Hypertriglyceridemia - Pipeline Insight, 2021

DelveInsights, Hypertriglyceridemia - Pipeline Insight, 2021, report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Hypertriglyceridemia Understanding
Hypertriglyceridemia: Overview
Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the good cholesterol, HDL (high-density lipoprotein).

"Hypertriglyceridemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.

Hypertriglyceridemia Emerging Drugs Chapters
This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypertriglyceridemia Emerging Drugs
ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.

MND-21: Mochida Pharmaceutical
MND-21, a therapeutic agent for hypertriglyceridemia which is being developed in collaboration with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. in China. Currently, it is in Phase III stage of clinical trial evaluation to treat Hypertriglyceridaemia.
Further product details are provided in the report..

Hypertriglyceridemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hypertriglyceridemia
There are approx. 22+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Mochida Pharmaceutical.

Phases
DelveInsights report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypertriglyceridemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.

Hypertriglyceridemia Report Insights
Hypertriglyceridemia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Hypertriglyceridemia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Hypertriglyceridemia drugs?
How many Hypertriglyceridemia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Hypertriglyceridemia and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Arrowhead Pharmaceuticals
Mochida Pharmaceutical
Ionis Pharmaceuticals
89bio
Regeneron Pharmaceuticals
Acasti Pharma Inc.
Staten Biotechnology BV
NorthSea Therapeutics B.V.
Afimmune
Rivus Pharmaceuticals
Novo Nordisk
Viking Therapeutics
Liminal BioSciences
Matinas BioPharma
Arbutus Biopharma
Better Therapeutics

Key Products
ARO-APOC3
MND-21
IONIS-APOCIII-LRx
BIO89-100
Evinacumab
CaPre
STT-5058
NST-1024
DS102
AKCEA-APOCIII-LRx
NST-4016
BT-005
HU 6
TKM-HTG
COR 003
MAT-9001
VK 1430
PBI 4050
Introduction
Executive Summary
Hypertriglyceridemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypertriglyceridemia DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
MND-21: Mochida Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
ARO-APOC3: Arrowhead Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
ARGX 116: argenx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
VK 1430: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..


Inactive Products
Comparative Analysis
Hypertriglyceridemia Key Companies
Hypertriglyceridemia Key Products
Hypertriglyceridemia- Unmet Needs
Hypertriglyceridemia- Market Drivers and Barriers
Hypertriglyceridemia- Future Perspectives and Conclusion
Hypertriglyceridemia Analyst Views
Hypertriglyceridemia Key Companies
Appendix

List Of Tables

Table 1 Total Products for Hypertriglyceridemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Hypertriglyceridemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Hypertriglyceridemia - Pipeline Insight, 2021

DelveInsights, Hypertriglyceridemia - Pipeline Insight, 2021, report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and

USD 2000 View Report

Hypertriglyceridemia (Cardiovascular) - Drugs in Development, 2021

Hypertriglyceridemia (Cardiovascular) - Drugs in Development, 2021Hypertriglyceridemia (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Hypertriglyceridemia pipeline landscape.The report provides comprehensive information on the therapeutics under development

USD 2000 View Report

Natural Killer Cell Therapies - Pipeline Insight, 2021

DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the

USD 3000 View Report

Binge-eating disorder - Pipeline Insight, 2021

DelveInsights, Binge-eating disorder - Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including

USD 1500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available